시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
망막 생물제제 시장 규모, 점유율, 성장 분석 : 약제 클래스별, 적응증별, 유통 채널별, 지역 - 산업 예측(2025-2032년)
Retinal Biologics Market Size, Share, Growth Analysis, By Drug Class (VEGF-A Antagonists, TNF-a Inhibitors), By Indication (Macular Degeneration, Diabetic Macular Edema), By Distribution Channel, By Region - Industry Forecast 2025-2032
상품코드 : 1630685
리서치사 : SkyQuest
발행일 : 2025년 01월
페이지 정보 : 영문 219 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,300 ￦ 7,652,000
PDF & Excel (Single User License) help
PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,200 ￦ 8,951,000
PDF & Excel (Multiple User License) help
PDF 및 Excel 보고서를 동일 사업장에서 2-5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,100 ￦ 10,250,000
PDF & Excel (Enterprise License) help
PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

세계의 망막 생물제제 시장 규모는 2023년에 229억 달러로 평가되며, 2024년 246억 4,000만 달러에서 2032년에는 442억 7,000만 달러로 성장하며, 예측 기간(2025-2032년)의 CAGR은 7.6%로 성장할 전망입니다.

인구 고령화에 따라 망막 질환, 특히 노인성 황반변성(AMD), 당뇨망막병증, 망막정맥폐쇄증 등의 유병률 증가는 시급한 문제입니다. 생명공학의 발전은 혁신적인 치료법에 대한 수요를 불러일으키고 있으며, 특히 유전자 치료와 세포치료가 인기를 끌고 있는 망막 생물제제 분야에서 이러한 경향이 두드러지고 있습니다. Foundation과 같은 유명한 단체들이 일반 대중의 인지도를 높이고 중요한 연구 구상을 지원하고 있습니다. 특히 중국, 브라질, 인도와 같은 신흥 시장은 의료 인프라의 개선과 당뇨병 유병률 증가에 힘입어 큰 성장세를 보이고 있습니다. 전반적으로 망막 생물제제 시장은 치료의 발전, 인식의 향상, 그리고 이러한 질병에 대한 전 세계적인 노력으로 인해 확대될 것으로 예상됩니다.

목차

서론

조사 방법

개요

시장 역학과 전망

주요 시장 인사이트

망막 생물제제 시장 규모 : 약제 클래스별

망막 생물제제 시장 규모 : 적응증별

망막 생물제제 시장 규모 : 유통 채널별

망막 생물제제 시장 규모

경쟁 정보

주요 기업 개요

결론과 권장사항

KSA
영문 목차

영문목차

Global Retinal Biologics Market size was valued at USD 22.9 billion in 2023 and is poised to grow from USD 24.64 billion in 2024 to USD 44.27 billion by 2032, growing at a CAGR of 7.6% during the forecast period (2025-2032).

The increasing prevalence of retinal diseases, notably age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion, is a pressing concern driven by aging populations. Advances in biotechnology have catalyzed demand for innovative treatment options, particularly in retinal biologics, where gene therapy and cell-based therapies are gaining traction. Notable organizations, including the Foundation Fighting Blindness and the American Macular Degeneration Foundation, are enhancing public awareness and supporting critical research initiatives. Emerging markets, especially in countries like China, Brazil, and India, are poised for significant growth, fueled by improved healthcare infrastructure and rising diabetes rates. Overall, the retinal biologics market is primed for expansion, driven by advancements in treatment, increasing awareness, and a concerted global effort to address these conditions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Retinal Biologics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Retinal Biologics Market Segmental Analysis

Global Retinal Biologics Market is segmented by Drug Class, Indication, Distribution Channel and region. Based on Drug Class, the market is segmented into VEGF-A Antagonists and TNF-a Inhibitors. Based on Indication, the market is segmented into Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Uveitis and Others. Based on Distribution Channel, the market is segmented into Institutional Sales, Retail Pharmacies, Mail Order Pharmacies and Retail Sales. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Retinal Biologics Market

One of the primary drivers of the Global Retinal Biologics market is the alarming rise in vision-related issues, particularly in the United States. According to data from the Centers for Disease Control and Prevention, millions are diagnosed with diabetic retinopathy, with many at risk of developing further complications that could severely affect their eyesight. The increasing incidence of this condition is expected to boost the demand for effective treatments, thereby propelling significant growth in the market. As a result, the escalating need for retinal biologics is anticipated to create a robust pathway for advancements and investment in this sector.

Restraints in the Global Retinal Biologics Market

One of the significant restraints in the Global Retinal Biologics market is the high cost associated with these therapies. These biologic drugs can be prohibitively expensive, limiting access for individuals in developing countries who struggle to afford them. Additionally, the complexity involved in the manufacturing and commercialization of retinal biologics, coupled with stringent regulatory requirements, poses further challenges. This combination of factors not only restricts the market potential but also creates barriers for patients needing these crucial treatments, ultimately hindering overall market growth and accessibility to life-changing therapies for those in need around the world.

Market Trends of the Global Retinal Biologics Market

The Global Retinal Biologics market is witnessing a significant trend towards genetic treatment approaches, driven by recent advancements in gene therapy research for retinal diseases, particularly inherited retinal dystrophies. These innovative therapies are transforming the landscape of retinal biologic drugs, offering targeted solutions that address the root causes of these conditions rather than just alleviating symptoms. As a result, the market is expected to experience robust growth, fueled by increasing investments in R&D, promising clinical trial outcomes, and a rising awareness of genetic therapies among patients and healthcare professionals. This shift underscores a broader movement towards personalized medicine in ophthalmology.

Table of Contents

Introduction

Research Methodology

Executive Summary

Market Dynamics & Outlook

Key Market Insights

Global Retinal Biologics Market Size by Drug Class & CAGR (2025-2032)

Global Retinal Biologics Market Size by Indication & CAGR (2025-2032)

Global Retinal Biologics Market Size by Distribution Channel & CAGR (2025-2032)

Global Retinal Biologics Market Size & CAGR (2025-2032)

Competitive Intelligence

Key Company Profiles

Conclusion & Recommendations

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기